Morning After pill informationAbortion pill (RU486) information for Dayton and Cincinnati, Ohio.

Click here to schedule an appointment

Abortion Pill (RU-486)

RU-486 (Mifeprex®), commonly referred to as the Abortion Pill*, is used in conjunction with another medication, Misoprostol, to end an early pregnancy. It is approved in Ohio for use within 70 days since the first day of a women’s last menstrual period.

The FDA approved regimen is a two-visit process as follows:

  • Mifepristone is given by mouth during the first office visit. Mifepristone blocks the progesterone hormone from sustaining the pregnancy, thereby ending the life of the fetus.
  • Misoprostol tablets are taken at home 48 hours later to cause contractions (cramps and heavy bleeding) in order to expel the fetus.
  • A physical exam is needed within 7-14 days by the healthcare provider to verify that the uterus is empty, that the abortion was complete, and that there are no immediate complications.

Risks, Side Effects and Limitations

  • Possible risks and side effects include cramping, nausea, vomiting, diarrhea, heavy bleeding, infection and in rare cases, death.
  • The FDA does not advise RU-486 for women who have anemia, bleeding disorders, liver or kidney disease, seizure disorders, acute inflammatory bowel disease, use blood-thinners, use an IUD, those who have been on long-term corticosteriod therapy, are allergic to Mifeprex® or Cytotec or other prostaglandins, or are unable to return for the follow-up visit.
  • Women must be less than 71 days in pregnancy as determined by ultrasound. Our women’s centers offer free ultrasounds.
  • Women with an ectopic pregnancy are at high-risk for serious health complications and RU-486 will not remove the pregnancy from the fallopian tube. Our women’s centers offer free ultrasounds to check for ectopic pregnancy.

 

*Our Women’s Centers do not provide or refer for abortion or the abortion pill.


FDA warning:

ru486-warning

Source: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111323.htm